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Table S1: Growth conditions for cell lines used.  
Cell Line Obtained from 
Type of 
Media 
% 
FBS  Media Supplements  
CaCo2 a,b AMGEN DMEM 20 100 U/mL PenStrep 
Colo205 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
Colo320DM a AMGEN RPMI 1640 10 100 U/mL PenStrep 
Colo678 a,b AMGEN DMEM 10 100 U/mL PenStrep 
CW2 a,b AMGEN DMEM 10 100 U/mL PenStrep 
DLD-1 a,b,c,d AMGEN RPMI 1640 10 100 U/mL PenStrep 
HCC2998 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
HCT116 a,b,c AMGEN McCoy's 5A 10 100 U/mL PenStrep 
HCT15 a,b,d AMGEN RPMI 1640 10 100 U/mL PenStrep 
HT29 a,b,d AMGEN McCoy's 5A 10 100 U/mL PenStrep 
KM12 a AMGEN RPMI 1640 10 100 U/mL PenStrep 
LoVo a AMGEN Ham's F-12K 10 100 U/mL PenStrep 
Ls1034 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
Ls123 a,b AMGEN DMEM 10 100 U/mL PenStrep 
Ls174T a,b AMGEN DMEM 10 100 U/mL PenStrep 
NCI-H716 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
NCI-H508 a AMGEN RPMI 1640 10 100 U/mL PenStrep, 2 mM GlutaMAX 
RKO a,b AMGEN DMEM 10 100 U/mL PenStrep 
SW1116 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW1463 a AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW403 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep, 2 mM GlutaMAX 
SW48 a,b AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW480 a,d AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW620 a,b,d AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW837 a AMGEN RPMI 1640 10 100 U/mL PenStrep 
SW948 a,b ATCC RPMI 1640 10 100 U/mL PenStrep, 2 mM GlutaMAX 
WiDr a,b,d AMGEN DMEM 10 100 U/mL PenStrep 
AN3-CA c AMGEN DMEM 10 100 U/mL PenStrep 
DU-145 c ATCC DMEM 10 100 U/mL PenStrep 
HCT-116N c -- RPMI 1640 10 
100 U/mL PenStrep, 2 mM L-glutamine, 0.1 mM 
non-essential amino acids, 1 mM sodium 
pyruvate, 400 ug/mL Geneticin (G418) 
HCT-116O c -- RPMI 1640 10 
100 U/mL PenStrep, 2 mM L-glutamine, 0.1 mM 
non-essential amino acids, 1 mM sodium 
pyruvate, 400 ug/mL Geneticin (G418) 
HEC-1-A c ATCC McCoy's 5A 10 100 U/mL PenStrep 
a Cell lines used in cytotoxicity assay  
b Cell lines used in whole cell uptake assay 
c Cell lines used in RhCy3 fluorescence assay 
d
 DLD-1/HCT15, HT29/WiDr, SW480/SW620 pairings are derived from a common patient. 
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Table S2: IC50 values of RhPPO and cisplatin in all tested cell lines.  
Cell Line IC50 RhPPO (μM) 
IC50 Cisplatin 
(μM) 
IC50 RhPPO 
/IC50 Cisplatin 
Cancer 
Type 
MMR Status, 
(Mutated Protein) 
CaCo-2 1.5 ± 0.8 9.5 ± 3.7 6.2 Colorectal MMR+ 
Colo 205 0.063 ± 0.03 36.4 ± 2.8 580 Colorectal MMR+ 
Colo 320DM 18.0 ± 2.9 9.5 ± 2.0 0.5 Colorectal MMR+ 
Colo 678 0.81 ± 0.15 18.2 ± 0.7 22.4 Colorectal MMR+ 
CW-2 9.2 ± 1.3 9.0 ± 2.1 1.0 Colorectal MMR−, (−MLH1) 
DLD-1 c 3.6 ± 0.3 10.7 ± 2.2 3.0 Colorectal MMR−, (−MSH6) 
HCC2998 a 1.6 ± 0.6 20.4 ± 1.4 12.6 Colorectal MMR+, (−POLE)  
HCT-116 c 0.25 ± 0.01 18.5 ± 0.9 73.3 Colorectal MMR−, (−MLH1) 
HCT-15 9.5 ± 2.5 16.1 ± 0.3 1.7 Colorectal MMR−, (−MSH6) 
HT-29 0.21 ± 0.01 22.1 ± 1.1 106 Colorectal MMR+ 
KM-12 0.83 ± 0.07 13.9 ± 0.9 16.7 Colorectal MMR−, (−MLH1) 
LoVo 1.7 ± 0.2 7.0 ± 1.2 4.0 Colorectal MMR−, (−MSH2) 
Ls1034 5.6 ± 0.3 14.4 ± 1.9 2.6 Colorectal MMR+ 
Ls123 0.23 ± 0.03 9.0 ± 7.0 39.7 Colorectal MMR+ 
Ls174T 2.0 ± 0.2 5.4 ± 0.6 2.8 Colorectal MMR−, (−MLH1) 
NCI-H716 1.8 ± 0.6 13.9 ± 2.9 7.7 Colorectal MMR+ 
NCI-H508 1.5 ± 0.4 8.8 ± 1.4 5.9 Colorectal MMR+ 
RKO 0.12 ± 0.01 11.6 ± 0.7 97.5 Colorectal MMR−, (−MLH1) 
SW-1116 4.4 ± 1.2 9.1 ± 1.4 2.1 Colorectal MMR+ 
SW-1463 1.6 ± 0.2 9.5 ± 1.1 6.0 Colorectal MMR+ 
SW-403 0.34 ± 0.04  9.1 ± 1.5 27.1 Colorectal MMR+ 
SW-48 0.34 ± 0.02 2.2 ± 0.2 6.4 Colorectal MMR−, (−MLH1) 
SW-480 c 0.44 ± 0.13 8.3 ± 0.6 12.0 Colorectal MMR+ 
SW-620 0.33 ± 0.04 4.8 ± 0.8 14.7 Colorectal MMR+ 
SW-837 1.8 ± 0.7 11.4 ± 1.3 6.2 Colorectal MMR+ 
SW-948 9.7 ± 1.9 22.1 ± 1.7 2.3 Colorectal MMR+ 
WiDr 0.13 ± 0.01  25.5 ± 14.1 198.7 Colorectal MMR+ 
AN3-CA c 0.086 ± 0.003 -- -- Endometrial MMR−, (−MLH1) 
DU-145 c 0.67 ± 0.04 -- -- Prostate MMR−, (−MLH1, PMS2) 
HEC-1-A c  0.39 ± 0.02 -- -- Endometrial MMR−, (−PMS2) 
HCT-116N b, c 1.12 ± 0.27 -- -- Colorectal MMR+ 
HCT-116O b, c 0.15 ± 0.06 -- -- Colorectal MMR−, (−MLH1) 
a HCC2998 is mutated in the POLE gene, leading to an increase in polymerase errors such as 
mismatches and indels. While it is not technically MMR−, it will have higher mismatch and 
indel occurrences than other MMR+ cell lines. 
b IC50 values from reference [5] 
c Cell lines used as the test set for the RhCy3 assay. Note that since the colorectal cancer cell 
lines examined in the cytotoxicity studies were primaily deficient in the MLH1 gene, this test set 
includes several cell lines of non-colorectal origin that span deficienicies in different MMR 
genes as well.   
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Table S3: Purity of genomic DNA extracted from the cancer cell lines used in this study as 
determined using a NanoDrop spectrophotometer. 
Phenotypea A260/A280b A260/A230c 
SW480-i 1.94 2.05 
SW480-ii 1.93 2.06 
SW480-iii 1.94 2.06 
   
HCT116N-i 2.02 2.02 
HCT116N-ii 2.00 2.04 
HCT116N-iii 2.01 2.02 
   
HCT116O-i 1.95 1.97 
HCT116O-ii 1.97 2.01 
HCT116O-iii 1.99 2.00 
   
HCT116-i 1.97 2.06 
HCT116-ii 1.98 2.05 
HCT116-iii 1.94 2.03 
   
AN3-CA-i 1.91 1.99 
AN3-CA-ii 1.92 1.99 
AN3-CA-iii 1.91 1.98 
   
DU-145-i 2.00 1.97 
DU-145-ii 1.95 1.90 
DU-145-iii 1.96 1.91 
   
HEC-1A-i 1.95 2.03 
HEC-1A-ii 1.97 2.06 
HEC-1A-iii 1.93 2.04 
   
DLD-1-i 2.00 2.04 
DLD-1-ii 1.94 1.98 
DLD-1-iii 1.99 2.06 
a For each phenotype there are three biological replicates (i, ii, iii).  
b The ratio of absorbance at 260 nm and 280 nm is used to assess the purity of DNA. A ratio of 
~1.8 is considered as “pure” for DNA; If the ratio is appreciably lower it may indicate the 
presence of protein, phenol or other contaminants that absorb strongly at or near 280 nm.  
c This ratio is used as a secondary measure of nucleic acid purity. The 260/230 values for “pure” 
nucleic acid are commonly in the range of 2.0 - 2.2. If the ratio is appreciably lower than 
expected, it may indicate the presence of contaminants which absorb at 230 nm.  
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Figure S1. Cytotoxicity of a therapeutic in 27 colorectal cancer cell lines. A) Dose response 
curves of cisplatin in MMR− and MMR+ CRC cell lines. B) Comparison of the IC50 values of 
RhPPO in MMR+ (MSS) and MMR− (MSI) cell lines shown as boxplots. The average IC50 of 
RhPPO in MMR+ cells is 3.22 μM and the median is 1.37 μM. The average IC50 of RhPPO in 
MMR− cells is 2.62 μM and the median is 1.28 μM. C) Comparison of the IC50 values of 
cisplatin in MMR+ and MMR− cell lines shown as boxplots. The average IC50 of cisplatin in 
MMR+ cells is 15.65 μM and the median is 12.09 μM. The average IC50 of cisplatin in MMR− 
cells is 10.38 μM and the median is 10.30 μM. D) Comparison of the IC50 values of RhPPO 
broken down based on mutated MMR (or POLE) protein (MMR+ = NA). For MLH1 deficient 
cells, the IC50 of RhPPO is 2.06 μM and the median is 0.59 μM.  
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Figure S2: A correlation between whole cell uptake and IC50 for RhPPO. MMR− cell lines are 
shown in red and MMR+ are shown in blue, with all cell lines labeled.   
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Figure S3. Scatterplots comparing fluorescence output of RhCy3 with gDNA versus the 
Log(IC50) of RhPPO in various cell lines. A) shows all data and has a Pearson’s r = -0.52, 
making it significant at the p < 0.2 level. B) By removing the possible outlier, DU145, the 
Pearson’s r increases to -0.81, which is significant at the p < 0.05 level. C) When comparing only 
MMR+ cell lines and MMR− cell lines with mutations in the MLH1 gene, r = -0.47 with 
significance at the p < 0.35 level. D) When comparing only MMR+ cell lines and MMR− cell 
lines that are not mutated in PMS2, r increases to -0.87 with significance at the p < 0.05 level.  
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Supplemental Discussion on RhCy3 as a reporter on gDNA lesions 
 
There is a clear relationship between the identity of the deficient MMR protein and 
RhCy3 fluorescence output. Titrations of RhCy3 with genomic DNA extracted from cell lines 
with a deficiency in the MLH1 protein (i.e. HCT116O, AN3-CA, DU-145, and HCT116) 
resulted in the highest fluorescence intensities, indicating there are an abundance of mismatches, 
indels, and/or abasic sites present in these cell lines. The final two MMR− cell lines, DLD-1 and 
HEC-1-A, display low fluorescence intensity that is comparable to the intensity observed for the 
MMR+ cell lines, HCT116N and SW480. It may be possible to explain the low intensity 
observed with DLD-1 and HEC-1-A by considering their specific MMR-deficiencies: MSH6 and 
PMS2, respectively. Functioning MMR generally involves two heterodimers, MutSα (MSH2 + 
MSH6) and MutLα (MLH1 + PMS2), however other homologues to these heterodimers also 
exist: MutSβ (MSH2 + MSH3), MutLβ (MLH1 + MLH2), and MutLγ (MLH1 + MLH3).[6] These 
different MutS and MutL homologues have different roles in the cell, with MutSα and MutLα 
correcting mismatches and some indels, and MutSβ, MutLβ, and MutLγ contributing to the 
correction of long and short indels but not mismatches. Therefore, a cell line deficient in MSH2 
or MLH1 cannot correct any mismatches or indels, but a cell line deficient in MSH6 or PMS2 
may still be able to correct some indels via MutSβ, MutLβ, and MutLγ homologues. Considering 
this, the fluorescence of DLD-1 and HEC-1-A may be relatively low because these cell lines 
have MMR machinery that can correct some indels, meaning they will have fewer total lesions 
than MLH1-deficient cells that correct neither mismatches nor indels. It is also of note that the 
baseline fluorescence in the presence of DNA from MMR+ cells and the variations between 
DNA from different MMR− cells may be due to RhCy3 binding abasic sites or other 
thermodynamically destabilized lesions that are not associated with MMR pathways. Overall 
RhCy3 shows great promise as a direct reporter on the number of thermodynamically 
destabilized lesions in gDNA, and it may also have the potential to be developed into an early 
diagnostic reporter of MMR-deficiencies in cells.  
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